---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-009384"
form_type: "8-K"
ticker: "WGRX"
cik: "0002030763"
company_name: "Wellgistics Health, Inc."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T18:15:12.681841+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Wellgistics launches medical food Forzet for GLP-1 muscle loss targeting $70B market

## Summary
- Forzet is a medical food for dietary management of muscle loss during weight loss therapies, aimed at GLP-1 drug users.
- GLP-1 agonist market forecast to grow from $70B (2025) to $201B (2030) per Grandview Research.
- Forzet has been evaluated in multiple controlled clinical studies (Type 2 diabetes, heart failure, COPD) in Europe.
- Product is classified as medical food, not FDA-approved drug; available OTC under physician supervision.
- Initial availability through Wellgistics affiliated pharmacy and select network pharmacies; no revenue guidance provided.

## SEC filing metadata
- accession: 0001493152-26-009384
- form_type: 8-K
- ticker: WGRX
- cik: 0002030763
- company_name: Wellgistics Health, Inc.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2030763/000149315226009384/0001493152-26-009384-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2030763/000149315226009384/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-009384
- JSON: https://secwatch.observer/filing/0001493152-26-009384.json
- Plain text: https://secwatch.observer/filing/0001493152-26-009384.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.